Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin/vinorelbine plus cetuximab vs cisplatin/vinorelbine in EGFR-expressing advanced NSCLC (phase III)
2004-001105-96Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck KGaA. Primary endpoint: overall survival time. Started Aug 2004; status: completed.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-001105-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001105-96.